Folashade Otegbeye
@DrShadeO
Followers
109
Following
175
Media
5
Statuses
81
Joined October 2021
The administration of allogeneic natural killer (NK) cells following a lymphodepleting chemotherapy regimen is emerging as a well-tolerated therapeutic approach in the management of various malignancies. Read more of @DrShadeO article now: https://t.co/TfolLDDLh1
3
4
24
A new $5.2 million grant from WRF will help develop a new clinical trials program between @fredhutch & @seattlechildren. The program, led by Dr. Folashade Otegbeye, will focus on first-in-human clinical studies of new therapeutics for rare cancers: https://t.co/UHv7HrktJn
0
1
2
A new $5.2M grant from the Washington Research Foundation will help launch a joint clinical trials program between Fred Hutch and @seattlechildren's, advancing first-in-human studies for rare cancers and other diseases that affect adults and children.
fredhutch.org
A new $5.2 million grant from the Washington Research Foundation will help develop a new clinical trials program between Fred Hutch Cancer Center and Seattle Children’s Research Institute.
0
1
5
⚠️Question for my CAR-T-treating colleagues⚠️ Which would you consider the most acceptable standard of care option for grade 2+ ICANS persistent or worsening after treatment with frontline dexamethasone? Please repost 🙏 #equipoise #clinicaltrial #CARTcelltherapy
4
12
17
People with darker skin have more melanin, which can act like a “natural sunscreen,” but if you have darker skin, you can still get skin cancer, sometimes in places that receive very little sun. #skincancer #sunscreen #skincare
0
1
2
Session chair Jennifer Adair of @fredhutch kicks off today’s opening plenary on gene therapy at #Tandem25.
0
3
3
Meet the next generation of hematology and oncology leaders! The Fred Hutch/UW Hematology-Oncology Fellows are at #Tandem25 presenting their latest findings in transplantation, cell therapies, immunology and more. @emilyliangmd @HannahRAbrams
0
3
26
Congratulations @masumi_ueda on a spectacular #Tandem25. In addition to her clinical trial report in the best abstracts plenary, she mentored medical students on two LTFU post-transplant clonal evolution studies also featured at the meeting. #NextGen mentor
Fred Hutch at #Tandem25: @masumi_ueda to present results of a novel drug regimen that shows great promise in preventing #cGVHD after transplant in people who received nonmyeloablative or reduced-intensity conditioning to treat a blood cancer. https://t.co/oq1KoAjaRY
2
2
11
Congratulations to two phenomenal clinicians who have excelled at leadership, mentorship and advocacy in the transplant and cell therapy field globally. @DrMarcosdelima your inspired and selfless service remains instructive for me, your lifelong mentee. 💐
Congratulations to ASTCT Public Service Award recipients Mary E. Flowers, MD, of @fredhutch and Marcos de Lima, MD, of @OhioState. #Tandem25
2
3
15
Congratulations to ASTCT Public Service Award recipients Mary E. Flowers, MD, of @fredhutch and Marcos de Lima, MD, of @OhioState. #Tandem25
2
7
39
Upcoming best abstract presentation at #Tandem25: Masumi Ueda Oshima, MD, will present the results of a phase II study on a combination of PTCy, cyclosporine, and sirolimus for patients with GVHD. Learn more: https://t.co/pDS2hf6zH5
0
2
9
Congratulations @ekimblepl on the @ASTCT New Investigator Award! Excited to see new approaches to CAR T cell therapy in AML. @fredhutch
1
7
24
Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger" for cGVHD, says Fred Hutch's @masumi_ueda. She will present the results, including updated data with longer follow-up of patients, on Feb. 14 at #Tandem25.
fredhutch.org
A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in preventing moderate to severe cGVHD after transplant in people who received...
0
2
9
Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger" for cGVHD, says Fred Hutch's @masumi_ueda. She will present the results, including updated data with longer follow-up of patients, on Feb. 14 at #Tandem25.
fredhutch.org
A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in preventing moderate to severe cGVHD after transplant in people who received...
1
4
24
"The fact that there wasn’t a major difference can offer some comfort to physicians and patients by showing that [allogeneic] transplantation does not result in higher acquisition of mutations," said @masumi_ueda. https://t.co/Tm5fLRKIhk
fredhutch.org
After an allogeneic stem cell transplant, a recipient’s body faces a daunting task: rebuilding the person’s blood-forming and immune systems from the ground up from a relatively small number of...
0
3
8
Applications for the 7th Annual Dr. Eddie Méndez Award is now open! This award recognizes outstanding and diverse #postdocs who are conducting #cancer, #infectiousdisease or #basicscience research. Apply by February 2, 2025 👉 https://t.co/SDmkIESwjb
#MendezSymposium
1
7
11
Gary Schwartz: “Dr. [Nathan] Berger’s YES summer program has profoundly impacted the education of students from our underrepresented community in cancer medicine. It is just one part of his legacy as our first @caseccc director.” Berger died on June 15. https://t.co/lAsdamMO6Y
cancerletter.com
Nathan Berger, professor of medicine, biochemistry, oncology, and genetics; the Hanna-Payne Professor of Experimental Medicine; the director of the Center for Science, Health, and Society; and a...
0
2
2
"[Nathan Berger's] contributions to oncology have been immense, marked by groundbreaking research, compassionate patient care, and unwavering commitment to advancing medical science." -@caseccc
https://t.co/lAsdamMO6Y
0
4
10